Specific vaccines against autoimmune diseases

Comptes Rendus de l'Academie des Sciences - Serie III

Volumn 322, Issue 11, 1999, Pages 933-938

  Sela, Michael ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmune diseases; Copolymer 1; Experimental allergic encephalomyelitis; Multiple sclerosis; Myasthenia gravis; Myelin basic protein; Specific vaccines

Indexed keywords

CHOLINERGIC RECEPTOR; EPITOPE; GLATIRAMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN; RECEPTOR SUBUNIT; T LYMPHOCYTE RECEPTOR; VACCINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; IMMUNOMODULATION; META ANALYSIS; MOUSE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; T LYMPHOCYTE ACTIVATION;

ANIMALIA;

EID: 0033230954     PISSN: 07644469     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0764-4469(00)87189-9     Document Type: Conference Paper

References (30)

1. Sela M., Arnon R., Teitelbaum D., Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis, Bull. Inst. Pasteur 88 (1990) 303-314.
2. Teitelbaum D., Arnon R., Sela M., Copolymer 1: From basic research to clinical application, Cell. Mol. Life Sci. 53 (1997) 24-28.
3. Webb C., Teitelbaum D., Arnon R., Sela M., In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalo-myelitis, Eur. J. Immunol. 3 (1973) 279-286.
4. Webb C., Teitelbaum D., Herz A., Arnon R., Sela M., Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids, Immunochemistry 13 (1976) 333-337.
5. Lando Z., Teitelbaum D., Arnon R., Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE, J. Immunol. 123 (1979) 2156-2160.
6. Lando Z., Teitelbaum D., Arnon R., The immunological response in mice unresponsive to experimental allergic encephalomyelitis, J. Immunol. 126 (1981) 1526-1528.
7. Abramsky O., Teitelbaum D., Arnon R., Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalo-myelitis, J. Neurol. Sci. 31 (1977) 433-438.
8. Bornstein M.B., Miller A.I., Teitelbaum D., Arnon R., Sela M., Multiple sclerosis: Trial of a synthetic polypeptide, Ann. Neurol. 11 (1982) 317-319.
9. Bornstein M.B., Miller AS., Lagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheilsmoller S., Spada V., Weiss W., Arnon R., Jacobsohn I., Teitelbaum D., Sela M., A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis, N. Engl. J. Med. 317 (1987) 408-414.
10. Bornstein M.B., Miller A., Slagle S., Weitzman M., Drexler E., Keilson M., Spada V., Weiss W., Appel S., Rolak L., Harati Y., Brown S., Arnon R., Jacobsohn I., Teitelbaum D., Sela M., A Placebo-controlled, Double-blind, Randomized, Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis, 41 (1991) 533-539.
11. Teitelbaum D., Aharoni R., Sela M., Arnon R., Cross reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1, Proc. Natl. Acad. Sci. USA 88 (1991) 9528-9532.
12. Aharoni R., Teitelbaum D., Sela M., Arnon R., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. USA 94 (1997) 10821-10826.
13. Aharoni R., Teitelbaum D., Sela M., Arnon R., Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1, J. Neuroimmunol. 91 (1998) 135-146.
14. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C.H., Kwon T., Brenner T., Arnon R., Sela M., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity, Proc. Natl. Acad. Sci. USA 91 (1994) 4872-4876.
15. Aharoni R., Teitelbaum D., Arnon R., Sela M., Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to the MHC blocking, Proc. Natl. Acad. Sci. USA 96 (1999) 634-639.
16. Meiner Z., Kott E., Schechter D., Nisipianu P., Korczyn A.D., Flechter S., Abramsky O., Copolymer 1 in relapsing-remitting multiple sclerosis: A multi-centre trial, in: Abramsky O., Ovadia H. (Eds.), Frontiers in Multiple Sclerosis: Clinical Research and Therapy, Martin Dunitz, London, 1997, pp. 213-221.
17. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.C., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis, Neurology 45 (1995) 65-70.
18. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.C., Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability, Neurology 50 (1998) 701-708.
19. Ford C.C., Brooks B.R., Cohen J.A., Coldstein J., Johnson K.P., Lisak, R.R., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.C., Sustained efficacy of glatiramer acetate for injection in a 5+ year trial of relapsing remitting MS, in: Basic Clinical Issues in Multiple Sclerosis Research, ACTRIMS, Montreal, Canada, 1998, p. 27.
20. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., Lahat N., Treatment of multiple sclerosis with copolymer 1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immunedeviation, J. Neuroimmunol. 92 (1998) 113-121.
21. Teitelbaum D., Arnon R., Sela M., Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1, Proc. Natl. Acad. Sci. USA 96 (1999) 3842-3847.
22. Vincent A., Newson-Davis J., Acetylcholine receptor antibody diagnostic test for myasthenia gravis: Results in 153 valid cases and 2967 diagnostic assays, J. Neurol. Neurosurg. Psych. 48 (1985) 1246-1252.
23. Karni A., Zisman E., Katz-Levy Y., Paas-Rozner M., Dayan M., Brautbar, C., Abramsky O., Sela M., Mozes E., Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor, Neurology 48 (1997) 1638-1642.
24. Kirshner S.L., Zisman E., Fridkin M., Sela M., Mozes E., Altered peptide ligands of a myasthenogenic epitope as modulators of specific t-cell responses, Scand. J. Immunol. 44 (1996) 512-521.
25. Katz-Levy Y., Kirshner S.L., Sela M., Mozes E., Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs, Proc. Natl. Acad. Sci. USA 90 (1993) 7000-7004.
26. Katz-Levy Y., Paas-Rozner M., Kirshner S.L., Dayan M., Zisman E., Fridkin M., Wirguin I., Sela M., Mozes E., A peptide composed of tandom analogs of two myasthenogenic T cell epitopes interferes with the specific autoimmune responses, Proc. Natl. Acad. Sci. USA 94 (1997) 3200-3205.
27. Kirshner S.L., Katz-Levy Y., Wirguin I., Argov Z., Mozes E., Fine specificity of T cell lines and clones that are capable of inducing autoimmune manifestations in mice, Cell Immunol. 157 (1994) 11-28.
28. Zisman E., Katz-Levy Y., Dayan M., Kirshner S.L., Paas-Rozner M., Karni A., Abramsky O., Brautbar C., Fridkin M., Sela M., Mozes E., Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis, Proc. Natl. Acad. Sci. USA 93 (1996) 4492-4497.
29. Zisman E., Brautbar C., Sela M., Abramsky O., Battat S., Kirshner S.L., Katz-Levy Y., Dayan M., Mozes E., Binding of peptides of the human acetylcholine receptor alpha-subunit to HLA class II of patients with myasthenia gravis, Human Immunol. 44 (1995) 121-130.
30. Paas-Rozner M., Faber-Elmann A., Sela M., Mozes E., Immunomodulation of myasthenia gravis associated autoimmune responses by an altered peptide ligand: Mechanisms of action, in: Christadoss P. (Ed.), The Myasthenia Gravis Workshop Proceedings, Narosa Publ. House, 1999.